Search - tctmd.com

Displaying 1 - 20 of 79

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Todd Neale

August 30, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Top General Cardiology and Prevention News of 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

TCTMD’s Top 10 Most Popular Stories for May 2024

Semaglutide Winning Streak Continues in CKD With FLOW

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content